Related Experiment Video
Updated: Jul 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Left Atrial Appendage Closure: A Narrative Review
Takashi Nagasaka1,2, Mamoo Nakamura3
1Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Insights
Atrial fibrillation (AF) increases stroke risk. Left atrial appendage closure (LAAC) offers a mechanical alternative to blood thinners, reducing bleeding events for patients with AF.
Area of Science:
- Cardiology
- Medical Devices
- Interventional Cardiology
Background:
- Atrial fibrillation (AF) is a prevalent cardiac arrhythmia linked to a higher risk of thromboembolic events, particularly in the elderly.
- Left atrial appendage (LAA) thrombus is a primary source of emboli in AF patients, leading to significant morbidity and mortality.
- Oral anticoagulation therapy is the standard preventive treatment but carries an increased risk of bleeding.
Purpose of the Study:
- To review the current perspectives and outcomes of left atrial appendage closure (LAAC) as a preventive intervention for thromboembolic events in AF patients.
- To evaluate LAAC as an alternative to pharmacologic therapy, focusing on its safety and efficacy.
- To highlight the advancements in transcatheter LAAC devices and their impact on patient outcomes.
Main Methods:
- This review synthesizes data from recent clinical trials and existing literature on transcatheter LAAC devices.
- It examines the evolution of LAAC device technology and its clinical performance.
- The review focuses on comparative outcomes between LAAC and traditional anticoagulation therapy.
Main Results:
- Transcatheter LAAC has emerged as a feasible mechanical intervention to prevent thromboembolic events.
- Newer generation LAAC devices demonstrate improved safety profiles and clinical outcomes.
- LAAC offers a viable alternative for patients at high risk of bleeding with oral anticoagulation.
Conclusions:
- Left atrial appendage closure is an effective strategy for reducing stroke risk in AF patients, especially those with contraindications to anticoagulation.
- Ongoing advancements in LAAC technology continue to enhance its safety and efficacy.
- LAAC represents a significant development in the management of AF-related thromboembolic risk.
Abstract:
Atrial fibrillation (AF) is the most common cardiac arrhythmia and the cause of thromboembolic events in elderly patients worldwide. AF is associated with a significantly increased risk of morbidity and mortality due to cardiac emboli, primarily from left atrial appendage (LAA) thrombus. Oral anticoagulation therapy is the standard treatment to effectively reduce the risk of thromboembolic events in patients with AF. However, anticoagulation treatment increases bleeding risk. LAA closure (LAAC) has recently been introduced as a feasible mechanical preventive intervention for thromboembolic events while minimizing the risk of bleeding. Transcatheter LAAC devices have evolved in the past decade, and several ongoing trials have demonstrated the improvements of safety and outcomes in newer generation devices. This review summarizes the current perspectives and outcomes regarding LAAC as an alternative to pharmacologic therapy.
Related Concept Videos
Hindsight Biases
Termination of Translation
Torts II
Torts III
Quasi-intentional torts in healthcare involve acts where intent is not directed to harm an individual but results in harm due to careless or reckless speech.
Eyewitness Memory
One such error is memory distortion, which occurs because human memory does not function like a...
Ending Relationships

